Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance.

Oh, Johnathan; Barve, Minal; Senzer, Neil; Aaron, Phylicia; Manning, Luisa; Wallraven, Gladice; Bognar, Ernest; Stanbery, Laura; Horvath, Staci; Manley, Meghan; Nemunaitis, John; Walter, Adam; Rocconi, Rodney P

Oh, Johnathan; Barve, Minal; Senzer, Neil; Aaron, Phylicia; Manning, Luisa; Wallraven, Gladice; Bognar, Ernest; Stanbery, Laura; Horvath, Staci; Manley, Meghan; Nemunaitis, John; Walter, Adam; Rocconi, Rodney P.

Afiliação

Oh J; Texas Oncology, P.A., Dallas, TX, United States.
Barve M; Texas Oncology, P.A., Dallas, TX, United States.
Senzer N; Mary Crowley Cancer Research Centers, Dallas, TX, United States.
Aaron P; Gradalis, Inc., Carrolton, TX, United States.
Manning L; Gradalis, Inc., Carrolton, TX, United States.
Wallraven G; Gradalis, Inc., Carrolton, TX, United States.
Bognar E; Gradalis, Inc., Carrolton, TX, United States.
Stanbery L; Gradalis, Inc., Carrolton, TX, United States.
Horvath S; Gradalis, Inc., Carrolton, TX, United States.
Manley M; Gradalis, Inc., Carrolton, TX, United States.
Nemunaitis J; Gradalis, Inc., Carrolton, TX, United States.
Walter A; Gradalis, Inc., Carrolton, TX, United States.
Rocconi RP; ProMedica, Toledo, OH, United States.

Gynecol Oncol Rep ; 34: 100648, 2020 Nov.

Article em En | MEDLINE | ID: mdl-33364285

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Gynecol Oncol Rep Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google